Squalene Purification via Segmented Distillation Temperatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing squalene from shark liver oil often result in contaminated products due to the risk of pathogens, human toxins, and allergens, making it unsuitable for pharmaceutical use without rigorous manufacturing standards.
Innovation Solution
A method involving purification and denaturing distillation at specific temperatures (T1 and T2) to produce squalene with high purity, removing impurities and allergens like parvalbumin, ensuring the product is safe for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If squalene is extracted from shark liver oil using conventional methods, then the production cost is low and the process is simple, but the product contains contaminants, pathogens, and allergens making it unsuitable for pharmaceutical use
Solution Approach 1:
The purification process is divided into multiple distinct stages: initial extraction, purification distillation at temperature T1, and denaturing distillation at temperature T2. Each stage targets specific contaminants, progressively improving product safety while maintaining manageable process complexity through systematic breakdown of the purification task.
Solution Approach 2:
The process utilizes temperature parameter changes to achieve different purification objectives. Purification distillation occurs at temperature T1 to remove volatile contaminants, while denaturing distillation occurs at higher temperature T2 to denature proteins and remove non-volatile contaminants. This parameter-based approach ensures pharmaceutical-grade purity without requiring overly complex equipment.
2Manufacturing precision
If purification distillation is carried out at temperature T1, then volatile impurities are removed, but non-volatile contaminants remain in the product
Solution Approach 1:
The process employs two distinct temperature parameters: T1 for purification distillation to remove volatile impurities, and T2 (where T2 > T1 and T2 ≥ 200°C) for denaturing distillation to remove non-volatile contaminants. This staged parameter approach maximizes purity while minimizing squalene loss by optimizing each distillation stage for its specific contaminant type.
Solution Approach 2:
The method exploits phase transition differences between squalene and various contaminants at different temperatures. At temperature T1, volatile contaminants transition to vapor phase and are removed. At temperature T2, proteins and non-volatile contaminants undergo denaturation and phase separation, enabling their removal while retaining squalene in the desired phase.
3Reliability
If denaturing distillation is carried out at temperature T2 ≥ 200°C, then proteins and non-volatile contaminants are removed, but energy consumption increases
Solution Approach 1:
The process performs preliminary purification distillation at the lower temperature T1 before conducting denaturing distillation at the higher temperature T2. This preliminary action removes volatile contaminants first, reducing the overall energy burden of the subsequent high-temperature denaturing step while ensuring comprehensive contaminant removal for pharmaceutical-grade safety.
Solution Approach 2:
The method utilizes controlled temperature parameter changes with T2 ≥ 200°C specifically for denaturing distillation. This parameter is optimized to achieve protein denaturation and removal of non-volatile contaminants while minimizing unnecessary energy consumption. The staged approach allows energy-intensive high-temperature processing to be applied only when necessary for specific contaminant types.
4Ease of manufacture
If shark liver oil is used as the source, then squalene can be obtained at low cost, but the product contains pathogens, toxins, and allergens
Solution Approach 1:
The manufacturing process segments contaminant removal into targeted stages: purification distillation at T1 addresses volatile contaminants, while denaturing distillation at T2 addresses proteins and non-volatile contaminants including allergens like parvalbumin. This segmented approach maintains ease of manufacture with conventional equipment while systematically eliminating harmful factors to achieve pharmaceutical-grade safety.
Solution Approach 2:
The process employs parameter changes in temperature (T1 and T2 ≥ 200°C) to selectively remove different types of harmful contaminants from shark liver oil-derived squalene. This approach maintains manufacturing simplicity while effectively addressing pathogens, toxins, and allergens through thermally-based separation and denaturation mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively purifies squalene, achieving a product with at least 99% purity and reducing contaminants, pathogens, and allergens, making it suitable for pharmaceutical use and safe for human administration.
Implementation Method 1
a purification distillation carried out at a temperature T1
Implementation Method 2
a denaturing distillation carried out at a temperature T2
Implementation Method 3
a denaturing distillation carried out at a temperature T2 wherein T2≥200° C.
Implementation Method 4
T1 and T2 are sufficient to cause squalene to boil
Data Source
AI summary
An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T1 (b) a denaturing distillation carried out at a temperature T2; wherein steps (a) and (b) may be performed in either order; T1 and T2 are sufficient to cause squalene to boil; T2>T1; and T2>200° C.